logo-loader

Poolbeg Pharma announce two US patents

Published: 03:28 30 May 2022 EDT

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) (AIM:POLB, OTCQB:POLBF) has been granted US patents protecting two key assets – POLB 001, a potential flu treatment, and POLB 002, a nasal spray for virus infections.

Jeremy Skillington says the firm is working with its advisors to broaden and expand the patent families for both early-stage drug candidates.

He says the additional US patent protection of POLB 001 and POLB 002 is an important step in the commercialisation of these novel infectious disease products'.

Poolbeg Pharma "continuing its campaign to find a partner" for POLB001

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on clinical-stage biopharmaceutical company Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF). Appiah starts by explaining the scale of the opportunity that Poolbeg is pursuing...

on 2/11/23
OSZAR »